For US residents only.

How Treatment May Help


Why Look to AFINITOR to Treat My Progressive GI NET?

In a clinical trial, patients with progressive gastrointestinal (GI) or lung neuroendocrine tumors (NET) lived for 7 months longer without the disease getting worse.

Chart showing 7-month improvement in progression-free survival with AFINITOR® (everolimus)

205 patients received AFINITOR® (everolimus) Tablets*

97 patients received sugar pills*

*Number includes patients with either lung or GI NET.


During the clinical trial, 2% of patients who took AFINITOR had their tumor size reduced, compared with 1% of patients who took a sugar pill.

Data has not shown a statistically significant increase in overall survival compared to a sugar pill.